A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Dose Study of SLN12140 Administered Subcutaneously or Intravenously in Healthy Adult Volunteers
Latest Information Update: 06 May 2025
At a glance
- Drugs SLN 12140 (Primary) ; SLN 12140 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Linno Pharmaceuticals
Most Recent Events
- 06 May 2025 New trial record